Search Results - "Halmos B"

The associations of CD4 count, CD4/CD8 ratio, and HIV viral load with survival from non-small cell lung cancer in persons living with HIV.

Authors: Klugman, M. Fazzari, M. Xue, X. et al.

Source: AIDS Care. Aug2022, Vol. 34 Issue 8, p1014-1021. 8p. 4 Charts, 1 Graph.

Subjects: Lung cancer complications, HIV infection prognosis, Lung cancer diagnosis, HIV-positive persons, HIV infections, Biomarkers, Confidence intervals, Viral load, Cancer patients, CD4 lymphocyte count

DNMT3A clonal hematopoiesis is associated with cardiovascular disease in women.

Authors: Halmos, B. Salzbrunn, J. B. Van Zeventer, I. A. et al.

Source: Cardiovascular Research. 2026 Supplement, Vol. 122, pi259-i259. 1p.

2082eTiP COPERNICUS: A multinational pragmatic phase II trial of subcutaneous (SC) amivantamab (Ami) in common EGFR-mutated (cEGFRm) NSCLC.

Authors: Halmos, B. Florez, N. Goldberg, S.B. et al.

Source: Annals of Oncology. 2025 Supplement 2, Vol. 36, pS1173-S1173. 1p.

Predictors of Early Durvalumab Discontinuation After Chemoradiotherapy for Non-Small Cell Lung Cancer.

Authors: Pennock, M.M. Halmos, B. III, W.R. Bodner et al.

Source: International Journal of Radiation Oncology, Biology, Physics. 2021 Supplement, Vol. 111 Issue 3, pe448-e449. 2p.

Subjects: Non-small-cell lung carcinoma, Proportional hazards models, Cancer invasiveness, Esophageal cancer, Chemoradiotherapy, Lungs, Heart tumors

Bmi1 Resistance Pathway and Immune Checkpoint Blockade in Lung Cancer.

Authors: Chaudhary, K.R. Halmos, B. Cheng, H. et al.

Source: International Journal of Radiation Oncology, Biology, Physics. 2021 Supplement, Vol. 111 Issue 3, pe432-e433. 2p.

Subjects: Immune checkpoint proteins, Lung cancer, Cisplatin, Laboratory mice, Small molecules, Lung tumors

Budget report.

Authors: Halmos, B. B., jr

Source: Water & Sewage Works; March 1967, Vol. 114, p111-112, 2p

Prognostic Value of FDG-PET Metrics for Advanced NSCLC Patients Treated with First-line Immunotherapy.

Authors: Andraos, T.Y. Halmos, B. Cheng, H. et al.

Source: International Journal of Radiation Oncology, Biology, Physics. 2020 Supplement, Vol. 108 Issue 3, pe116-e117. 2p.

Subjects: Immune checkpoint inhibitors, Immunotherapy

Who Benefits Most from Adjuvant Durvalumab after Chemoradiotherapy for Non-Small Cell Lung Cancer?

Authors: Ohri, N. Halmos, B. Bodner III, W.R. et al.

Source: International Journal of Radiation Oncology, Biology, Physics. 2020 Supplement, Vol. 108 Issue 3, pe85-e86. 2p.

Subjects: Non-small-cell lung carcinoma, Chemoradiotherapy, Rectal cancer

Extreme lymphoplasmacytosis and hepatic failure associated with sulfasalazine hypersensitivity reaction and a concurrent EBV infection—case report and review of the literature.

Authors: Halmos, B. Anastopoulos, H. T. Schnipper, L. E. et al.

Source: Annals of Hematology. Apr2004, Vol. 83 Issue 4, p242-246. 5p.

Does Disease Burden on PET Predict Outcomes for Advanced NSCLC Patients Treated With First-Line Immunotherapy?

Authors: Andraos, T.Y. Halmos, B. Cheng, H. et al.

Source: International Journal of Radiation Oncology, Biology, Physics. 2021 Supplement, Vol. 111 Issue 3, pe428-e428. 1p.

Subjects: Non-small-cell lung carcinoma, Overall survival, Proportional hazards models, Prognosis, Disease progression

Daily Step Counts Predict Outcomes for Locally Advanced Non-Small Cell Lung Cancer Patients Treated with Concurrent Chemoradiotherapy.

Authors: Ohri, N. Halmos, B. Bodner III, W.R. et al.

Source: International Journal of Radiation Oncology, Biology, Physics. Sep2019 Supplement, Vol. 105, pE524-E525. 2p.

Subjects: Chemoradiotherapy, Non-small-cell lung carcinoma, Cancer patients

168TiP KEYNOTE-A86: Phase III, randomized, open-label study of first-line subcutaneous (SC) vs intravenous (IV) pembrolizumab with platinum doublet chemotherapy in metastatic squamous or nonsquamous non-small cell lung cancer (NSCLC).

Authors: Halmos, B. Cobb, P. Johnson, M.L. et al.

Source: Annals of Oncology. 2021 Supplement 7, Vol. 32, pS1456-S1456. 1p.

FDG-PET Metrics in Advanced Non-Small Cell Lung Cancer (NSCLC): A Modern Review and Meta-Analysis.

Authors: Berkowitz, A.C. Halmos, B. Cheng, H. et al.

Source: International Journal of Radiation Oncology, Biology, Physics. 2020 Supplement, Vol. 108 Issue 3, pe121-e121. 1p.

Subjects: Non-small-cell lung carcinoma, Meta-analysis

Results of the Afatinib Expanded Access Program (EAP): Efficacy and Safety: Metastatic Non-Small Cell Lung Cancer.

Authors: Kim, E.S. Halmos, B. Kohut, I.F. et al.

Source: International Journal of Radiation Oncology, Biology, Physics. Nov2014 Supplement, Vol. 90 Issue 5, pS40-S40. 1p.

Subjects: Protein-tyrosine kinase inhibitors, Drug efficacy, Lung cancer treatment, Medication safety, Metastasis

Lung cancer research and treatment: global perspectives and strategic calls to action.

Authors: Meyer, M.-L. Peters, S. Mok, T.S. et al.

Source: Annals of Oncology. Dec2024, Vol. 35 Issue 12, p1088-1104. 17p.

Characterizing First Events in LA-NSCLC Patients Treated with Chemoradiotherapy.

Authors: Pennock, M.M. III, W. R. Bodner Halmos, B. et al.

Source: International Journal of Radiation Oncology, Biology, Physics. 2023 Supplement, Vol. 117 Issue 2, pe49-e49. 1p.

Subjects: Non-small-cell lung carcinoma, Disease relapse, Progression-free survival, Chemoradiotherapy, Disease progression, Rectal cancer

Does Adjuvant Durvalumab Improve Local Control Following Chemoradiotherapy for Non-Small Cell Lung Cancer?

Authors: Zakharia, A. III, W.R. Bodner Halmos, B. et al.

Source: International Journal of Radiation Oncology, Biology, Physics. 2022 Supplement, Vol. 114 Issue 3, pS164-S164. 1p.

Subjects: Non-small-cell lung carcinoma, Proportional hazards models, Chemoradiotherapy, Rectal cancer

Simpson's paradox - aggregating and partitioning populations in health disparities of lung cancer patients.

Authors: Fu, P. Panneerselvam, A. Clifford, B. et al.

Source: Statistical Methods in Medical Research. Dec2015, Vol. 24 Issue 6, p937-948. 12p.

Disruption of the EGFR E884–R958 ion pair conserved in the human kinome differentially alters signaling and inhibitor sensitivity.

Authors: Tang, Z. Jiang, S. Du, R. et al.

Source: Oncogene. 1/29/2009, Vol. 28 Issue 4, p518-533. 16p. 1 Color Photograph, 1 Black and White Photograph, 2 Diagrams, 3 Graphs.

Dual MET-EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer.

Authors: Tang, Z. Du, R. Jiang, S. et al.

Source: British Journal of Cancer. 9/16/2008, Vol. 99 Issue 6, p911-922. 12p. 1 Color Photograph, 2 Black and White Photographs, 3 Graphs.